BRAF and melanoma: The aim of our analysis is to describe prescription patterns, recurrence, and toxicity rates of adjuvant treatments for resected stage III/IV melanoma in daily practice, including comparing physicians’ preferences for ICI versus BRAFi/MEKi for BRAF V600E/K mutant melanoma.